Treatment of refractory conjunctivitis associated to dupilumab with topical pimecrolimus applied to the eyelid skin

Alvise Sernicola,Irene Gattazzo,Federico Di Staso,Domenico Giordano,Alessandro Capalbo,Flavia Persechino,Gianluca Scuderi,Severino Persechino

DOI: https://doi.org/10.1111/dth.13134

2019-11-01

Dermatologic Therapy

Abstract:Patients with atopic dermatitis commonly experience ophthalmic complications, and a higher incidence of conjunctivitis has been observed during treatment with dupilumab.We present the case of a 49‐year‐old woman with persistent severe atopic dermatitis who complained of refractory conjunctivitis associated with dupilumab. Ocular examination showed features of atopic conjunctivitis for which an external topical application to the eyelids of pimecrolimus 10 mg/g cream was prescribed. The patient showed substantial clinical remission after only 12 days. This case was remarkable as the medication applied externally to the eyelid skin was effective in treating the conjunctival involvement possibly due to penetration of pimecrolimus through the eyelid layers. Further studies are needed to support the use of this drug for dupilumab‐related conjunctivitis.This article is protected by copyright. All rights reserved.

dermatology